New study probes genetic clues in lungs of fibrosis patients
NCT ID NCT07373288
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to understand how a gene called HOXB7 and related molecules behave in the lungs and blood of people with pulmonary fibrosis, a condition that causes lung scarring. Researchers will collect lung tissue and blood samples from 80 adults to look for biomarkers that might help track the disease. The goal is to learn more about fibrosis, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROSIS, PULMONARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Azienda Ospedaliero Universitaria Policlinico di Modena
RECRUITINGModena, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can umbilical cord stem cells ease a scarring lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care